Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 20, 2019

Primary Completion Date

December 16, 2020

Study Completion Date

December 28, 2020

Conditions
Hen Egg Allergy
Interventions
BIOLOGICAL

AR201 powder

AR201 powder (Hen Egg allergen formulation) provided in capsules

BIOLOGICAL

Placebo powder

Placebo powder provided in capsules

Trial Locations (11)

21162

Chesapeake Clinical Research, Inc., White Marsh

55402

Clinical Research Institute Inc, Minneapolis

72202

Arkansas Children's Hospital, Little Rock

83616

Idaho Allergy LLC, dba Idaho Allergy and Research, Eagle

90274

Peninsula Research Associates, Rolling Hills Estates

92123

Allergy & Asthma Medical Group and Research Center, A.P.C, San Diego

94598

Allergy and Asthma Clinical Research dba Bay Area Allergy, Walnut Creek

95117

Allergy & Asthma Associates of Santa Clara Valley Research Center, San Jose

98115

Seattle Allergy & Asthma Research Institute dba ASTHMA, Inc. Clinical Research Center, Seattle

30060-8950

Atlanta Allergy & Asthma Clinic, PA, Marietta

07712

Atlantic Research Center, LLC, Ocean City

Sponsors
All Listed Sponsors
lead

Aimmune Therapeutics, Inc.

INDUSTRY

NCT04056299 - Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy | Biotech Hunter | Biotech Hunter